bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
When compared to patients with type 2 diabetes, MODY patients are often more sensitive to sulphonylureas, such that a lower dose should be used to initiate treatment to avoid hypoglycaemia. Patients with MODY less often suffer from obesity and insulin resistance than those with ordinary type 2 diabetes (for whom insulin sensitizers like metformin or the thiazolidinediones are often preferred over the sulfonylureas).
=== Pharmacokinetics === The 2C drugs are orally active. They are metabolized by O-demethylation and deamination. This is mediated specifically by monoamine oxidase (MAO) enzymes MAO-A and MAO-B, whereas cytochrome P450 enzymes appear to metabolize only some 2C drugs and to have only a very small role.
Jack Watson was born on May 2, 1939, in Casey, Iowa, to Jesse H. and Anne Watson. Jack grew up in a town of about 1,000 residents in northern Iowa, Nora Springs. His father was the area's school superintendent and he had one brother. After graduating from Nora Springs High School 1957, he went to Iowa State University, majoring in chemistry and taking part in the University’s Air Force ROTC program for four years which accounts for the four years he spent on active duty in California and Texas. Before serving his Air Force obligation, after graduation Iowa State with a degree in Chemical Technology in 1961, he went to graduate school at the Massachusetts Institute Technology (MIT). At MIT, Watson was a PhD candidate in the laboratory of Klaus Biemann, one of the most notable experts in organic mass spectrometry at the time. As soon as he graduated from MIT, Watson reported for duty in the United States Air Force in the San Francisco Bay area. A friend of his from high school, introduced Watson to Judith Sjoberg. Not long after that, they were married and moved to Brooks Air Base in San Antonio, Texas. After completing his tour of duty in the Air Force, Watson took a one-year postdoctoral position in Strasbourg France at the Institut de Chimie, Université de Strasbourg under the direction of Robert Wolf. During this time and through the licensing of the Watson-Biemann gas separator to Thomson-CSF, for use in a gas chromatograph-mass spectrometer they ware manufacturing at the time, Watson made everlasting ties to the French Mass Spectrometry community.
After releasing Half-Life 2 in 2004, Valve began developing a trilogy of episodic sequels, planning to release shorter games more frequently. Half-Life 2: Episode One was released in 2006, followed by Episode Two in 2007, which ended on a cliffhanger. Episode Three was scheduled for 2008, but was canceled. The Half-Life: Alyx project lead, Robin Walker, said that Valve uses the Half-Life series to "solve some interesting collision of technology and art that had reared itself", but had failed to find a unifying idea that provided a sense of "wonderment, or opening, or expansion" for Episode Three. After the release of Left 4 Dead in 2008, Valve abandoned episodic development and made several failed attempts to develop further Half-Life projects. They decided to complete their new engine, Source 2, before beginning a new game, as developing Half-Life 2 and the Source engine simultaneously had created problems. In 2016 and 2017, the Half-Life writers Marc Laidlaw, Erik Wolpaw, Jay Pinkerton and Chet Faliszek left Valve. Coupled with Valve's support for their other franchises, journalists took the departures as an indicator that new Half-Life games were no longer in development. Walker blamed the lack of progress on Valve's flat management structure, whereby employees decide what to work on themselves. The team decided they would be happier if they worked together on a large project, even if it was not everyone's preferred choice. By 2013, Valve was experimenting with VR using Half-Life 2 as a basis.
Sources: en.wikipedia.org
=== 1. FC Lokomotive (1966–1990) === East German football went through a general reorganization in 1965, creating football clubs as centres of high-level football, during which the football department of SC Leipzig was separated from the sports club and reformed into football club 1. FC Lokomotive Leipzig, while rival Chemie Leipzig continued as a Betriebssportgemeinschaft (BSG), or corporate team. Like most East German clubs, it was assigned to a publicly owned enterprise as its "sponsor". In the case of Lokomotive, the providing enterprise was Deutsche Reichsbahn—the East German state railways—hence the name. The club's fortunes improved somewhat as they almost always finished well up the league table, but they were unable to win the top honour in the DDR-Oberliga, with losing final appearances in 1967, 1986, and 1988. Lok earned a clutch of East German Cups (FDGB Pokal) with victories in 1976, 1981, 1986, and 1987, against failed appearances in the Cup final in 1970, 1973, and 1977. They also won the UEFA Intertoto Cup in 1966 and made an appearance in the 1987 final of the European Cup Winners' Cup, falling 0–1 to Johan Cruyff's Ajax after a Marco van Basten goal.
=== Safety === In general, somatostatin receptor antagonists were noted to be well tolerated. However, due to its mechanism of action, it may decrease the effectiveness of SSA therapy (Somatostatin Analogue Therapy), however other studies indicate SSA may not need to be stopped if somatostatin antagonists are used to label tumors instead of agonists. As somatostatin can cause inhibition of hormone production that uses it as a mediating hormone, it has an antiproliferative effect on cell tumors, especially in neuroendocrine tumors. Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative effects. Somatostatin receptor antagonists can bind to the receptors without activating them , antagonizing the therapeutic inhibitory effects of SSA therapy. Slow intravenous injection might be used until further safety data becomes available.
Crutzen (1933–2021), Dutch chemist, winner of the 1995 Nobel Prize in Chemistry for work on atmospheric chemistry, especially in relation to ozone Ana Maria Cuervo (born 1966), Spanish-American physician, researcher, and cell biologist, best known for work on autophagy Marie Curie (1867–1934), Polish and French radiation physicist, discovered the elements radium and polonium, 1903 Nobel Prize in Physics, 1911 Nobel Prize in Chemistry Pierre Curie (1859–1906), French physicist and chemist, 1903 Nobel Prize in Physics for work on radioactivity Robert Curl (1933–2022), American chemist, winner of 1996 Nobel Prize in Chemistry for discovery of the fullerene class of materials Theodor Curtius (1857–1928), German chemist known for the Curtius rearrangement, and also discovery of diazoacetic acid, hydrazine and hydrazoic acid Anthony Czarnik (born 1957), American chemist and inventor known for work on fluorescent chemosensors Emil Czyrniański (1824–1888), Polish chemist, known for developing chemical nomenclature in Polish
The outermost layer of the gastrointestinal wall consists of several layers of connective tissue and is either of serosa (below the diaphragm) or adventitia above the diaphragm. Regions of the gastrointestinal tract within the peritoneum (called Intraperitoneal) are covered with serosa. This structure consists of connective tissue covered by a simple squamous epithelium, called the mesothelium, which reduces frictional forces during digestive movements. The intraperitoneal regions include most of the stomach, first part of the duodenum, all of the small intestine, caecum and appendix, transverse colon, sigmoid colon and rectum. In these sections of the gut there is clear boundary between the gut and the surrounding tissue. These parts of the tract have a mesentery. Regions of the gastrointestinal tract behind the peritoneum (called retroperitoneal) are covered with adventitia. They blend into the surrounding tissue and are fixed in position (for example, the retroperitoneal section of the duodenum usually passes through the transpyloric plane). The retroperitoneal regions include the oral cavity, esophagus, pylorus of the stomach, distal duodenum, ascending colon, descending colon and anal canal.
Hodgkin and Huxley approached the problem by developing a set of differential equations for the parameters that govern the ion channel states, known as the Hodgkin-Huxley equations. These equations have been extensively modified by later research, but form the starting point for most theoretical studies of action potential biophysics.
Sources: en.wikipedia.org
=== COVID-19 pandemic === On 20 January 2020, Xi commented for the first time on the emerging COVID-19 pandemic in Wuhan, and ordered "efforts to curb the spread" of the virus. He gave premier Li Keqiang some responsibility over the COVID-19 response, in what has been suggested by The Wall Street Journal was an attempt to potentially insulate himself from criticism if the response failed. The government initially responded to the pandemic with a lockdown and censorship, with the initial response causing widespread backlash within China. Xi met with Tedros Adhanom Ghebreyesus, the director-general of the World Health Organization (WHO), on 28 January. Der Spiegel reported that in January 2020 Xi pressured Tedros Adhanom to hold off on issuing a global warning about the outbreak of COVID-19 and hold back information on human-to-human transmission of the virus, allegations denied by the WHO. On 5 February, Xi met with Cambodian prime minister Hun Sen in Beijing, the first foreign leader allowed into China since the outbreak. After the COVID-19 outbreak got under control in Wuhan, Xi visited the city on 10 March. After getting the outbreak in Wuhan under control, Xi has favoured what has officially been termed "dynamic zero-COVID policy" that aims to control and suppress the virus as much as possible within the country's borders. This has involved local lockdowns and mass-testing.
== Associated organizations == Clinical Chemistry and Laboratory Medicine is the official journal of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). It is also the official journal of the Association of Clinical Biochemists in Ireland, the Belgian Society of Clinical Chemistry, the German United Society of Clinical Chemistry and Laboratory Medicine, the Greek Society of Clinical Chemistry-Clinical Biochemistry, the Italian Society of Clinical Biochemistry and Clinical Molecular Biology, the Slovenian Association for Clinical Chemistry, and the Spanish Society for Clinical Biochemistry and Molecular Pathology.
When anchoring a molecule to a solid support, intermediates cannot be isolated from one another without cleaving the molecule from the resin. Since many of the traditional characterization techniques used to track reaction progress and confirm product structure are solution-based, different techniques must be used. Gel-phase 13C NMR spectroscopy, MALDI mass spectrometry, and IR spectroscopy have been used to confirm structure and monitor the progress of solid-phase reactions. Gordon et al., describe several case studies that utilize imines and peptidyl phosphonates to generate combinatorial libraries of small molecules. To generate the imine library, an amino acid tethered to a resin is reacted in the presence of an aldehyde. The authors demonstrate the use of fast 13C gel phase NMR spectroscopy and magic angle spinning 1 H NMR spectroscopy to monitor the progress of reactions, showing that most imines could be formed in as little as 10 minutes at room temperature when trimethyl orthoformate was used as the solvent. The formed imines were then derivatized to generate 4-thiazolidinones, B-lactams, and pyrrolidines. The use of solid-phase supports greatly simplifies the synthesis of large combinatorial libraries of compounds. This is done by anchoring a starting material to a solid support and then running subsequent reactions until a sufficiently large library is built, after which the products are cleaved from the support.
Since their conceptualization in 1998, several advances have been made in terms of the variety of types of microneedles that can be fabricated. The 5 main types of microneedles are solid, hollow, coated, dissolvable/dissolving, and hydrogel-forming. The distinct characteristic of each type of MNs allow a variety of clinical applications, including diagnosis and treatment. Micro-sized needles in a microneedles (MNs) device can be as short as 25μm or even 2000μm in length depending on their types.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.